UNC0321

CAT: 0804-HY-10930-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10930-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 63 pM and with assay-dependent IC50 values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC50 values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications[1][3].
CAS Number
[1238673-32-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; GCGR; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/UNC0321.html
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CN1CCC(NC2=C3C=C(OC)C(OCCOCCN(C)C)=CC3=NC(N4CCN(C)CCC4)=N2)CC1
Molecular Formula
C27H45N7O3
Molecular Weight
515.69
Precautions
H302, H315, H319, H335
References & Citations
[1]Liu F, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53 (15) :5844-57.|[2]Liu F, et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J Med Chem. 2011 Sep 8;54 (17) :6139-50.|[3]Nie J. UNC0321 inhibits high glucose induced apoptosis in HUVEC by targeting Rab4. Biomed Pharmacother. 2020 Nov;131:110662.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EHMT1/GLP/KMT1D; EHMT2/G9a/KMT1C

Popular Products